https://www.selleckchem.com/pr....oducts/valemetostat-
When categorized by disease severity, CDVA improved in less severe eyes (stage 1) and more severe eyes (stage 2 or 3; P=0.049 and P=0.00009, respectively). Total OIS was not significantly different between baseline and last follow-up (P=0.754); however the epithelial defect score was significantly less (P=0.034). Twenty-four of 31 eyes (77.4%) continued wearing the PROSE device, with a mean daily wearing time of 10.0±4.6 hrs. CONCLUSIONS In patients with LSCD, vision improved and the OIS remained stable with PROSE, suggesti
Me gusta
Comentario
Compartir
